DFTX Definium Therapeutics, Inc. - Common Shares
NASDAQ · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 6, 2026DFTX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
DFTX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 29 de Agosto de 2022 | 1-for-15 | Reverso |
Sobre Definium Therapeutics, Inc. - Common Shares Visão geral da empresa da Wikipedia
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
History
MindMed was founded in May 2019 by Stephen Hurst and Jamon Rahn.
MindMed initially focused on developing treatments for opioid withdrawal and opioid use disorder with 18-MC, a non-hallucinogenic molecule based on the psychoactive alkaloid ibogaine. In June 2019, it acquired the 18-MC drug development program, previously funded by the National Institute on Drug Abuse, and in September began to prepare 18-MC for a Phase I FDA clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder.
MindMed was the first psychedelic pharmaceutical company to go public, listing on the Canadian NEO Exchange in March of 2020 through a reverse takeover with the Canadian gold mining company Broadway Gold Mining. It began trading on the Nasdaq as MNMD in April 2021 after being approved for an uplisting from the OTC Markets.
In a press release on June 9, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a director on the board, to be replaced by then CDO Robert Barrow.
On February 26, 2021, MindMed closed its acquisition of digital health startup HealthMode. In connection with the acquisition, Daniel Karlin MD, CEO of HealthMode, was appointed to the position of CMO of the company.
On August 25, 2022, the first patient was dosed in a phase 2b trial for treatment of MM120 (now DT120) in generalized anxiety disorder (GAD). The study would go on to recruit 198 participants. The majority of trial participants experienced statistically significant improvements in their GAD scores, leading to the approval of multiple phase three human trials.
On January 12, 2026, MindMed rebranded to Definium Therapeutics.
Research
In March 2020, MindMed announced that it had partnered with NYU Langone to launch a clinical training program to train psychiatrists in psychedelic therapies and research to advance and deploy psychedelic medicines. The company committed $5 million to establish the center, which will also explore 18-MC and the use of drugs, including psilocybin-assisted therapy for alcohol use disorder.
In April 2020, the company entered into a long-term partnership with University Hospital Basel's Liechti Lab, gaining rights to more than ten years of the lab's data related to LSD, MDMA, and other psychedelic substances. The development of a novel compound designed to shorten the duration or stop an LSD experience that would allow LSD to be more widely used in a therapeutic environment was subsequently announced. Later that year a clinical trial studying the effects of DMT, the primary psychoactive ingredient in ayahuasca, and clinical trials combining MDMA and LSD were announced. A study to better understand and compare the altered states of consciousness induced by psilocybin and LSD began in August 2020,
and in October a Phase 1 study at the Liechti Lab on the acute dose dependent effects of LSD was completed. The results of the study were published by the American College of Neuropsychopharmacology in the journal Neuropsychopharmacology. In September 2021, further results were presented by Matthias Liechti, head of the Liechti Lab, at the INSIGHT Conference in Berlin. The results included the first clinical evidence on the comparative effects of LSD and psilocybin, stating 100mcg of LSD produced the same acute perceptual effects as a dose of 20 mg of psilocybin in healthy volunteers. Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.
In December 2020, MindMed entered into an investigator-sponsored study agreement with Maastricht University in the Netherlands. The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.
In March 2024, the FDA granted breakthrough therapy designation to MindMed's form of LSD (MM120; now DT120) for the treatment of generalized anxiety disorder. This decision was influenced by a drug trial in which approximately half of the participants experienced significant relief from their symptoms. Positive results in clinical trials against general depression symptoms and generalized anxiety disorder were reported in 2026.
=== Ongoing clinical trials ===
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | DFTX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E | -18.2 | · | · | · | |
| P/S | 897.1 | · | · | · | |
| P/B (MRQ) | 5.5 | · | · | · | |
| EV / EBITDA | -20.0 | · | · | · | |
| Price / Cash Flow (Preço / Fluxo de Caixa) | -28.1 | · | · | · | |
| EV / Revenue (EV / Receita) | 807.0 | · | · | · | |
| Price / Tangible Book (Preço / Valor Patrimonial Tangível) | 11.8 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | DFTX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| ROA | -49.5%média 5A ≈-55.1% | ≈-55.1% | · | · | |
| ROE | -71.0%média 5A ≈-64.1% | ≈-64.1% | · | · | |
| ROIC | -44.6% | · | · | · |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | DFTX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | 0.0média 5A ≈0.1 | ≈0.1 | · | · | |
| Índice de liquidez corrente (MRQ) | 6.9média 5A ≈7.6 | ≈7.6 | · | · | |
| Quick Ratio (Índice de Liquidez Seca) | 6.2média 5A ≈7.4 | ≈7.4 | · | · | |
| Dívida de Longo Prazo / Patrimônio Líquido (MRQ) | 0.0média 5A ≈0.1 | ≈0.1 | · | · | |
| Interest Coverage (Cobertura de Juros) | -30.3 | · | · | · |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | DFTX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 212.0% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Ainda não há dados fundamentais suficientes para calcular este grupo de proporções.
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 6, 2026 | $-1.44 | $-0.56 | -158.2% |
| 31 de Março de 2026 | Mai 7, 2026 | $-0.71 | $-0.50 | -41.4% |
| 31 de Dezembro de 2025 | $-0.50 | $-0.50 | -0.52% | |
| 30 de Setembro de 2025 | $-0.78 | $-0.51 | -52.6% | |
| 30 de Junho de 2025 | $-0.50 | $-0.37 | -34.5% | |
| 31 de Março de 2025 | $-0.27 | $-0.37 | 27.6% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $65M | $52M | $36M | $35M | $19M | |
| SG&A Expense | $49M | $39M | $42M | $30M | $59M | $14M | |
| Operating Expenses | $166M | $104M | $94M | $66M | $94M | $33M | |
| Operating Income | $-166M | $-104M | $-94M | $-66M | $-94M | $-33M | |
| Interest Expense | $5M | $2M | $920.0K | · | · | · | |
| Other Non-op | $-17M | $-5M | $-2M | $10M | $-339.0K | $-907.0K | |
| Pretax Income | $-184M | $-109M | $-96M | $-57M | $-94M | $-34M | |
| Income Tax | $0 | · | · | · | $-1M | · | |
| Net Income | $-184M | $-109M | $-96M | $-57M | $-93M | $-34M | |
| EPS (Basic) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| EPS (Diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| Shares (Basic) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| Shares (Diluted) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| EBITDA | $-166M | $-104M | $-94M | $-66M | $-94M | · |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $274M | $100M | $142M | $134M | $80M | |
| Short-term Investments | $154M | $0 | · | · | · | · | |
| Prepaid Expense | $8M | $8M | $4M | $4M | $4M | $1M | |
| Current Assets | $419M | $282M | $104M | $146M | $137M | $82M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $0 | |
| Intangibles | · | $0 | $527.0K | $4M | $7M | · | |
| Other Non-current Assets | $862.0K | $613.0K | $224.0K | $331.0K | · | · | |
| Total Assets | $440M | $302M | $125M | $170M | $164M | $82M | |
| Accounts Payable | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | $20M | $13M | $12M | $6M | $6M | $986.0K | |
| Current Liabilities | $67M | $39M | $32M | $18M | $10M | $3M | |
| Other Non-current Liabilities | $496.0K | · | $32.0K | $1M | $2M | · | |
| Total Liabilities | $108M | $61M | $46M | $19M | $12M | $6M | |
| Total Debt | $41M | $22M | $14M | · | · | · | |
| Common Stock | · | · | $0 | · | · | · | |
| Retained Earnings | $-583M | $-399M | $-290M | $-194M | $-138M | $-45M | |
| AOCI | $1M | $819.0K | $343.0K | $627.0K | $1M | $284.0K | |
| Stockholders' Equity | $332M | $241M | $78M | $151M | $152M | $76M | |
| Liabilities + Equity | $440M | $302M | $125M | $170M | $164M | $82M | |
| Shares Outstanding | 98,776,265 | 75,100,763 | 41,101,303 | 37,979,136 | 28,126,414 | · |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Deferred Tax | · | · | · | · | $-1M | · | |
| Amort. of Intangibles | $0 | $527.0K | $3M | $3M | $3M | $0 | |
| Operating Cash Flow | $-132M | $-79M | $-64M | $-50M | $-46M | $-24M | |
| Investing Cash Flow | $-152M | $0 | · | · | $-297.0K | · | |
| Stock Issued | $0 | $984.0K | $8M | $42M | $82M | $72M | |
| Net Stock Activity | $0 | $984.0K | $8M | $42M | $82M | · | |
| Financing Cash Flow | $267M | $253M | $22M | $59M | $99M | $97M | |
| Net Change in Cash | $-16M | $174M | $-42M | $9M | $53M | $73M | |
| Taxes Paid | $0 | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| Net Margin | · | · | -2052.6% | -3799.1% | 25915.3% | · | |
| Pretax Margin | · | · | -2052.6% | -3799.1% | 26237.6% | · | |
| EBITDA Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| ROA | -49.5% | -50.9% | -65.0% | -34.0% | -75.8% | · | |
| ROE | -71.0% | -43.2% | -110.0% | -37.3% | -58.9% | · | |
| ROIC | -44.6% | · | · | · | -61.1% | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 | · | |
| Quick Ratio | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 | · | |
| Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| Interest Coverage | -30.3 | -45.5 | · | · | · | · |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | -0.0 | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.36 | $3.21 | $1.90 | $3.97 | · | · | |
| Revenue / Share | · | · | $0.12 | $0.05 | · | · | |
| Cash Flow / Share | $-1.47 | $-1.12 | $-1.64 | $-1.62 | · | · | |
| Cash / Share | $2.61 | $3.65 | $2.43 | $3.74 | · | · | |
| EPS (TTM) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 212.0% | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $4M | $5M | $1M | $-359.0K | · | |
| Net Income TTM | $-184M | $-109M | $-96M | $-57M | $-93M | · | |
| Market Cap | $1.32B | $523M | · | · | · | · | |
| Enterprise Value | $952M | $271M | · | · | · | · | |
| P/E | -6.5 | -4.5 | · | · | · | · | |
| P/S | 321.2 | 126.9 | · | · | · | · | |
| P/B | 4.0 | 2.2 | · | · | · | · | |
| P / Tangible Book | 4.2 | 2.4 | · | · | · | · | |
| P / Cash Flow | -10.1 | -6.6 | · | · | · | · | |
| EV / EBITDA | -5.7 | -2.6 | · | · | · | · | |
| EV / Revenue | 231.1 | 65.8 | · | · | · | · | |
| Earnings Yield | -15.4% | -22.1% | · | · | · | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $41M | $34M | $31M | $30M | $23M | $22M | $17M | $15M | $12M | $12M | $13M | $15M | $13M | $9M | $8M | |
| SG&A Expense | $26M | $18M | $14M | $15M | $11M | $9M | $11M | $8M | $10M | $10M | $11M | $8M | $14M | $8M | $5M | $9M | |
| Operating Expenses | $75M | $59M | $48M | $46M | $41M | $32M | $32M | $25M | $24M | $22M | $22M | $22M | $29M | $21M | $14M | $17M | |
| Operating Income | $-75M | $-59M | $-48M | $-46M | $-41M | $-32M | $-32M | $-25M | $-24M | $-22M | $-22M | $-22M | $-29M | $-21M | $-14M | $-17M | |
| Interest Expense | $1M | $1M | $1M | $1M | $2M | $602.0K | $656.0K | $727.0K | $466.0K | $434.0K | $439.0K | $328.0K | $77.0K | $76.0K | · | · | |
| Other Non-op | $-84M | $-18M | $-3M | $-22M | $-2M | $9M | $-2M | $11M | $19M | $-32M | $-2M | $4M | $54.0K | $-4M | $9M | $498.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-5M | $-16M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Net Income | $-159M | $-77M | $-50M | $-67M | $-43M | $-23M | $-35M | $-14M | $-6M | $-54M | $-24M | $-18M | $-29M | $-25M | $-5M | $-16M | |
| EPS (Basic) | $-1.44 | $-0.71 | $-0.51 | $-0.78 | $-0.50 | $-0.27 | $-0.14 | $-0.18 | $-0.08 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| EPS (Diluted) | $-1.44 | $-0.71 | $-0.43 | $-0.78 | $-0.50 | $-0.35 | $0.13 | $-0.27 | $-0.26 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| Shares (Basic) | 110,684,720 | 108,790,941 | · | 85,885,516 | 85,347,677 | 85,067,855 | · | 77,909,441 | 71,912,323 | 47,860,757 | · | 39,720,007 | 38,576,394 | 38,077,251 | · | 29,296,333 | |
| Shares (Diluted) | 110,684,720 | 108,790,941 | · | 85,885,516 | 85,347,677 | 87,091,461 | · | 80,238,688 | 75,304,101 | 47,860,757 | · | 39,720,007 | 38,576,394 | 38,077,251 | · | 29,296,333 | |
| EBITDA | $-75M | $-59M | · | $-46M | $-41M | $-32M | · | $-25M | $-24M | $-22M | · | $-22M | $-29M | $-21M | · | $-17M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $655M | $263M | $258M | $20M | $33M | $83M | $274M | $295M | $243M | $252M | $100M | $118M | $117M | $129M | $142M | $155M | |
| Short-term Investments | $429M | $111M | $154M | $189M | $150M | $130M | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $8M | $7M | $8M | $7M | $6M | $9M | $8M | $4M | $5M | $3M | $4M | $2M | $3M | $3M | $4M | $2M | |
| Current Assets | $1.09B | $381M | $419M | $216M | $189M | $222M | $282M | $299M | $248M | $255M | $104M | $120M | $120M | $132M | $146M | $157M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $527.0K | $1M | $2M | $3M | $4M | $4M | |
| Other Non-current Assets | $880.0K | $812.0K | $862.0K | $1M | $1M | $606.0K | $613.0K | $493.0K | $534.0K | $144.0K | $224.0K | $229.0K | $268.0K | $300.0K | $331.0K | · | |
| Total Assets | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Accounts Payable | $7M | $7M | $5M | $8M | $4M | $2M | $2M | $2M | $3M | $8M | $4M | $8M | $9M | $2M | $2M | $824.0K | |
| Accrued Liabilities | $37M | $25M | $20M | $19M | $15M | $11M | $13M | $9M | $8M | $10M | $12M | $10M | $10M | $7M | $6M | $7M | |
| Current Liabilities | $157M | $81M | $67M | $65M | $38M | $30M | $39M | $33M | $42M | $65M | $32M | $31M | $35M | $24M | $18M | $26M | |
| Other Non-current Liabilities | $549.0K | $559.0K | $496.0K | $519.0K | $543.0K | · | · | · | · | $15.0K | $32.0K | $349.0K | $992.0K | $1M | $1M | $1M | |
| Total Liabilities | $194M | $122M | $108M | $106M | $80M | $53M | $61M | $58M | $66M | $79M | $46M | $46M | $36M | $25M | $19M | $27M | |
| Total Debt | $36M | $41M | · | $40M | $41M | $22M | · | $24M | $24M | $14M | · | $14M | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | $0 | $0 | · | $0 | · | · | · | · | · | |
| Retained Earnings | $-819M | $-660M | $-583M | $-532M | $-465M | $-422M | $-399M | $-364M | $-350M | $-345M | $-290M | $-266M | $-248M | $-219M | $-194M | $-190M | |
| AOCI | $417.0K | $824.0K | $1M | $1M | $807.0K | $802.0K | $819.0K | $821.0K | $833.0K | $836.0K | $343.0K | $777.0K | $362.0K | $641.0K | $627.0K | $743.0K | |
| Stockholders' Equity | $919M | $279M | $332M | $131M | $185M | $223M | $241M | $262M | $202M | $196M | $78M | $96M | $106M | $130M | $151M | $154M | |
| Liabilities + Equity | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Shares Outstanding | 134,365,950 | 104,044,508 | 98,776,265 | 76,774,057 | 75,803,251 | 75,511,375 | 75,100,763 | 81,590,491 | 72,075,076 | 71,163,720 | 41,101,303 | 40,094,708 | 38,807,159 | 38,290,111 | 37,979,136 | 37,541,115 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amort. of Intangibles | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $527.0K | $771.0K | $800.0K | $800.0K | $791.0K | $800.0K | $800.0K | |
| Operating Cash Flow | $-53M | $-43M | $-43M | $-30M | $-30M | $-29M | $-25M | $-17M | $-20M | $-17M | $-21M | $-17M | $-14M | $-13M | $-13M | $-9M | |
| Investing Cash Flow | $-317M | $42M | $35M | $15M | $-40M | $-162M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | $3M | $3M | $1M | $583.0K | $730.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $583.0K | · | · | |
| Financing Cash Flow | $762M | $5M | $246M | $749.0K | $20M | $1M | $4M | $69M | $11M | $169M | $3M | $17M | $1M | $583.0K | $416.0K | $58M | |
| Net Change in Cash | $393M | $5M | $238M | $-13M | $-49M | $-191M | $-22M | $52M | $-9M | $153M | $-18M | $804.0K | $-13M | $-13M | $-12M | $49M |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| Net Margin | · | · | · | · | · | · | · | · | · | · | · | -1541.1% | -2222.0% | -1932.6% | · | -4579.2% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -4579.2% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| ROA | -23.1% | -22.8% | · | -24.2% | -16.0% | -8.5% | · | -5.9% | -2.9% | -25.2% | · | -11.1% | -21.1% | -16.3% | · | -18.2% | |
| ROE | -28.8% | -30.7% | · | -34.2% | -22.1% | -11.2% | · | -7.6% | -3.8% | -33.3% | · | -14.4% | -25.3% | -18.6% | · | -21.5% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -11.1% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 4.7 | · | 3.3 | 5.0 | 7.3 | · | 9.0 | 5.9 | 3.9 | · | 3.9 | 3.4 | 5.5 | · | 6.0 | |
| Quick Ratio | 6.9 | 4.6 | · | 3.2 | 4.8 | 7.0 | · | 8.9 | 5.8 | 3.9 | · | 3.8 | 3.3 | 5.4 | · | 5.9 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| Interest Coverage | -60.9 | -47.6 | · | -35.8 | -17.5 | -53.4 | · | -34.1 | -52.5 | -51.2 | · | · | · | · | · | · |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.84 | $2.68 | · | $1.70 | $2.45 | $2.95 | · | $3.21 | $2.80 | $2.75 | · | $2.39 | $2.73 | $3.40 | · | $4.09 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | · | · | $0.03 | $0.03 | $0.03 | · | $0.01 | |
| Cash Flow / Share | · | $-0.39 | · | · | · | $-0.34 | · | · | · | $-0.35 | · | · | · | $-0.35 | · | · | |
| Cash / Share | $4.88 | $2.52 | · | $0.26 | $0.44 | $1.10 | · | $3.62 | $3.37 | $3.55 | · | $2.94 | $3.01 | $3.38 | · | $4.12 | |
| EPS (TTM) | $-3.36 | $-2.42 | · | $-1.50 | $-0.99 | $-0.75 | · | $-2.25 | $-2.43 | $-2.93 | · | $-1.88 | $-1.99 | $-1.83 | · | $-2.41 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $5M | · | $5M | $5M | $5M | · | $5M | $5M | $5M | · | $5M | $4M | $3M | · | $276.0K | |
| Net Income TTM | $-354M | $-238M | · | $-168M | $-115M | $-78M | · | $-98M | $-102M | $-125M | · | $-77M | $-75M | $-63M | · | $-69M | |
| Market Cap | $6.32B | $1.97B | · | $905M | $492M | $442M | · | $464M | $520M | $669M | · | · | · | · | · | · | |
| Enterprise Value | $5.27B | $1.63B | · | $736M | $350M | $251M | · | $193M | $301M | $431M | · | · | · | · | · | · | |
| P/E | -14.0 | -7.8 | · | -7.9 | -6.6 | -7.8 | · | -2.5 | -3.0 | -3.2 | · | · | · | · | · | · | |
| P/S | 1306.4 | 406.5 | · | 187.1 | 101.7 | 91.3 | · | 96.0 | 107.4 | 138.3 | · | · | · | · | · | · | |
| P/B | 6.9 | 7.1 | · | 6.9 | 2.7 | 2.0 | · | 1.8 | 2.6 | 3.4 | · | · | · | · | · | · | |
| P / Tangible Book | 7.0 | 7.6 | · | 8.2 | 3.0 | 2.2 | · | 1.9 | 2.9 | 3.8 | · | · | · | · | · | · | |
| P / Cash Flow | · | -46.1 | · | · | · | -15.0 | · | · | · | -40.3 | · | · | · | · | · | · | |
| EV / Revenue | 1089.9 | 337.7 | · | 152.2 | 72.4 | 52.0 | · | 39.9 | 62.2 | 89.0 | · | · | · | · | · | · | |
| Earnings Yield | -7.1% | -12.8% | · | -12.7% | -15.2% | -12.8% | · | -39.5% | -33.7% | -31.2% | · | · | · | · | · | · |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Margem Operacional % | · | · | -2012.6% | -4436.9% | 26143.2% |
| Lucro líquido | $-184M | $-109M | $-96M | $-57M | $-93M |
| EPS Diluído | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.1 | 0.1 | 0.2 | · | · |
| Índice de liquidez corrente | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 |
| Índice de Liquidez Seca | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 |
Ainda não há dados fundamentais suficientes para construir esta demonstração.
Investidores institucionais (13F) 389 declarantes · $5.1B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 163 | 28 | 120 | 65 | · |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado. Variação vs trimestre anterior não mostrada: a cobertura de registrantes difere demais entre esses dois trimestres para uma comparação confiável.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $528.392.511 | 11.232.834 | 10,30% | Ações |
| Avoro Capital Advisors LLC | $338.165.292 | 7.188.888 | 6,59% | Ações |
| Driehaus Capital Management LLC | $322.001.783 | 6.845.276 | 6,28% | Ações |
| Capital World Investors | $252.497.690 | 5.367.723 | 4,92% | Ações |
| FMR LLC | $223.577.402 | 4.752.921 | 4,36% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $171.482.802 | 3.644.813 | 3,34% | Ações |
| STATE STREET CORP | $144.195.946 | 3.065.390 | 2,81% | Ações |
| Capital International Investors | $139.398.806 | 2.963.410 | 2,72% | Ações |
| Octagon Capital Advisors LP | $138.768.000 | 2.950.000 | 2,71% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $138.755.487 | 2.949.734 | 2,71% | Ações |
| Deep Track Capital, LP | $129.360.000 | 2.750.000 | 2,52% | Ações |
| Commodore Capital LP | $94.080.000 | 2.000.000 | 1,83% | Ações |
| GOLDMAN SACHS GROUP INC | $84.712.079 | 1.800.852 | 1,65% | Ações |
| CITADEL ADVISORS LLC | $79.431.133 | 1.688.587 | 1,55% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $77.541.959 | 1.648.426 | 1,51% | Ações |
| RA CAPITAL MANAGEMENT, L.P. | $70.560.000 | 1.500.000 | 1,38% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $69.922.796 | 1.486.454 | 1,36% | Ações |
| JANUS HENDERSON GROUP PLC | $67.226.955 | 3.556.041 | 1,31% | Ações |
| Siren, L.L.C. | $66.772.951 | 1.419.493 | 1,30% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65.216.256 | 1.386.400 | 1,27% | Opção de compra |
| MARSHALL WACE, LLP | $61.102.420 | 1.298.946 | 1,19% | Ações |
| NORTHERN TRUST CORP | $55.000.956 | 1.169.238 | 1,07% | Ações |
| AMERIPRISE FINANCIAL INC | $54.018.997 | 1.148.363 | 1,05% | Ações |
| Nuveen, LLC | $51.993.971 | 1.105.314 | 1,01% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $50.971.415 | 1.083.576 | 0,99% | Ações |
| Woodline Partners LP | $47.211.273 | 1.003.641 | 0,92% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $47.040.000 | 1.000.000 | 0,92% | Ações |
| Boxer Capital Management, LLC | $46.969.440 | 998.500 | 0,92% | Ações |
| TWO SIGMA INVESTMENTS, LP | $43.362.319 | 921.818 | 0,85% | Ações |
| Balyasny Asset Management L.P. | $42.217.365 | 897.478 | 0,82% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $38.934.679 | 827.693 | 0,76% | Ações |
| Holocene Advisors, LP | $37.470.841 | 796.574 | 0,73% | Ações |
| AWM Investment Company, Inc. | $36.916.992 | 784.800 | 0,72% | Ações |
| Bank of New York Mellon Corp | $36.562.821 | 777.271 | 0,71% | Ações |
| Polar Capital Holdings Plc | $36.561.981 | 777.253 | 0,71% | Ações |
| ALLIANCEBERNSTEIN L.P. | $34.082.124 | 1.803.287 | 0,66% | Ações |
| EVENTIDE ASSET MANAGEMENT, LLC | $33.398.400 | 710.000 | 0,65% | Ações |
| NEUBERGER BERMAN GROUP LLC | $32.341.834 | 687.539 | 0,63% | Ações |
| Qube Research & Technologies Ltd | $32.123.663 | 682.901 | 0,63% | Ações |
| Candriam S.C.A. | $28.874.744 | 614.425 | 0,56% | Ações |
| ArrowMark Colorado Holdings LLC | $26.533.806 | 564.069 | 0,52% | Ações |
| Catalio Capital Management, LP | $26.468.091 | 562.672 | 0,52% | Ações |
| Blackstone Inc. | $26.418.228 | 561.612 | 0,52% | Ações |
| Integral Health Asset Management, LLC | $25.872.000 | 550.000 | 0,50% | Ações |
| BAMCO INC /NY/ | $24.465.880 | 520.108 | 0,48% | Ações |
| UBS Group AG | $23.494.928 | 499.467 | 0,46% | Ações |
| FRANKLIN RESOURCES INC | $22.871.742 | 486.219 | 0,45% | Ações |
| Point72 Asset Management, L.P. | $22.766.419 | 483.980 | 0,44% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22.155.840 | 471.000 | 0,43% | Opção de venda |
| Ensign Peak Advisors, Inc | $21.925.626 | 466.106 | 0,43% | Ações |
Executivos da empresa 16 insiders · 9 diretores · 9 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Robert Barrow | Chief Executive Officer | 25 de Setembro de 2026 S | 2.213.090 | 0 | 5 | $-3.981.146 |
| Brandi Roberts | Chief Financial Officer | 25 de Setembro de 2026 S | 394.528 | 0 | 2 | $-259.172 |
| Schond L. Greenway | Chief Financial Officer | 25 de Março de 2024 F | 211.057 | 0 | 0 | $0 |
| Miri Halperin Wernli | Executive President | 21 de Agosto de 2024 M | 202.405 | 0 | 0 | $0 |
| Dan Karlin | Chief Medical Officer | 25 de Setembro de 2026 S | 792.846 | 0 | 4 | $-1.070.502 |
| Matthew T. Wiley | Chief Commercial Officer | 25 de Setembro de 2026 S | 359.036 | 0 | 2 | $-242.358 |
| Mark Sullivan | Chief Legal Officer | 25 de Setembro de 2026 S | 494.228 | 0 | 4 | $-1.445.540 |
| Carrie Liao | Chief Accounting Officer | 25 de Março de 2025 S | 144.923 | 0 | 0 | $0 |
| Cynthia W. Hu | Chief Legal Officer&Secretary | 24 de Março de 2022 A | 1.200.000 | 0 | 0 | $0 |
| Andreas Krebs | Conselheiro | 18 de Setembro de 2026 M | 21.402 | 0 | 0 | $0 |
| Carol A Vallone | Conselheiro | 18 de Setembro de 2026 M | 22.296 | 0 | 0 | $0 |
| Roger Adsett | Conselheiro | 11 de Junho de 2026 A | 3.555 | 0 | 0 | $0 |
| Roger Crystal | Conselheiro | 11 de Junho de 2026 A | 24.289 | 0 | 0 | $0 |
| Suzanne Louise Bruhn | Conselheiro | 11 de Junho de 2026 A | 24.289 | 0 | 0 | $0 |
| David W Gryska | Conselheiro | 11 de Junho de 2026 A | 19.900 | 0 | 0 | $0 |
| Brigid Makes | Conselheiro | 1 de Junho de 2022 A | 158.706 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 22 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 2,13% | 10.109 NS | 31 de Julho de 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,18% | 12.558 NS | 31 de Julho de 2026 | N-PORT |
| IHE · iShares Trust | 1,12% | 479.902 SH | 11 de Setembro de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,36% | 139.235 SH | 19 de Agosto de 2026 | Diário |
| IBB · iShares Trust | 0,36% | 974.814 SH | 11 de Setembro de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,34% | 9.504 SH | 2 de Outubro de 2026 | Diário |
| IWO · iShares Trust | 0,32% | 1.221.670 SH | 11 de Setembro de 2026 | Diário |
| NUSC · Nushares ETF Trust | 0,31% | 90.473 NS | 31 de Julho de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,20% | 86.461 SH | 19 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,19% | 748.959 SH | 19 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,18% | 62.307 NS | 31 de Julho de 2026 | N-PORT |
| IWM · iShares Trust | 0,16% | 3.329.545 SH | 11 de Setembro de 2026 | Diário |
| ESML · iShares Trust | 0,10% | 73.991 SH | 11 de Setembro de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,08% | 331.180 SH | 19 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,07% | 1.486.454 SH | 19 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 52.257 NS | 31 de Julho de 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,06% | 103.206 NS | 31 de Julho de 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 6.834 SH | 11 de Setembro de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 17.940 SH | 2 de Outubro de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 10.703 SH | 19 de Agosto de 2026 | Diário |
| IWV · iShares Trust | 0,01% | 34.866 SH | 10 de Setembro de 2026 | Diário |
| ITOT · iShares Trust | 0,01% | 161.931 SH | 11 de Setembro de 2026 | Diário |
DFTX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
Preço-alvo de 12 meses
17 analistas · 2026-09-27Alvo médio $71.65 +91,6%
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| DFTX | $1.32B | -6.5 | 212.0% | · | -71.0% | · |
| BLTE | $6.29B | -69.2 | · | · | -16.9% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | · |
| MANE | · | · | · | · | 82.6% | · |
| EWTX | $2.64B | -15.2 | · | · | -30.2% | · |
| INDV | · | 21.9 | 4.3% | 17.0% | -118.3% | 80.2% |
| OGN | $1.87B | 10.0 | -2.9% | 3.0% | 25.2% | 53.3% |
| AMLX | $1.33B | -7.9 | -77.1% | · | -61.2% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.